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We describe here a direct radioimmunoassay (RIA) for the determination of 6-sulfatoxymelatonin (aMT6s) in plasma, with iodinated aMT6s as tracer. The aMT6s antiserum was raised in rabbit by immunization with a bovine serum albumin conjugate, giving negligible crossreactivities for related compounds. The low limit ofdetection (15 pmol/L) allowed a direct assay that required only a 100-FL plasma sample. Dilutions of plasma and of synthetic aMT6s gave the same parallel response in the RIA. A preliminary study showed a circadian variation in healthy volunteers, with mean concentrations ranging from 52 (at 1600-2100 h) to 378 pmol/L (at 0400 h), whereas this rhythm was abolished in pinealomectomized patients. After administration of melatonin orally, or by infusion, the aMT6s concentrations in plasma concorded with previous data on aMT6s production and pharmacokinetics, with aMT6s being cleared from plasma more slowly than melatonin. This assay should have practical application in the development of new pharmaceutical formulations that minimize the hepatic metabolism of melatonin.
AddItIonal Keyphrases:
pharmacokinetics meiafonin circadian pineal activity Melatonin, the major indole compound synthesized by the pineal gland, is metabolized mainly by hydroxylation at the 6-position (1) and conjugated with sulfate and glucuronide (2). 6-Sulfatoxymelatonin (aMT6s) is the major melatonin metabolite in humans (3)4 Similar to melatomn, the concentration of aMT6s in plasma increases at night and can be used as a marker of circadian pineal activity. The first radioinimunoassay of aMT6s in plasma involved a tritiated tracer and needed a relatively large plasma sample (0.5 mL) (4). Because iodinated tracers of higher specific activity allow moresensitive assays than do the tritiated tracers, we developed an 1251 RIA for aMT6s in plasma. The analytical and physiological validations are reported here. The concentration of melatonin in plasma was determined according to the method of Claustrat et al. (5) .
Materials and Methods

Procedures
Synthesis of 6-sulfatoxymelatonin.
We synthesized aMT6s according to the method of Leone et al. (6) and Jones et a!. (7) . In brief, we dissolved 6-hydroxymelathnm in dimethylformamide (DMF), and cooled the solution to 4 #{176}C. We then added slowly a solution of chlorosulfonic acid in DMF at 4#{176}C. After 30 mm at 4#{176}C, we purified the reaction mixture by passing it through a Florisil column. Using TLC on silica gel, we located and identified, by reference to the solvent front (RF), the reaction products after separation on the Florisil column. The chromatographic system was butanol/acetic acid/water (4/1/1 by vol). After being sprayed with Prochazka's reagent-a mixture of 10 mL of hydrochloric acid (250 mLIL), 10 mL of formaldehyde (350 mLIL), and 20 mL of ethanol-and heating to 100 #{176}C, aMT6s
was visible as a blue spot.
The aMT6s identification (RF = 0.53) was based on a aMT6s standard extracted from urine from a healthy volunteer who had been given 1 mg of melatonin orally.
After TLC analysis, the fractions containing aMT6s were pooled. Removal of the solvent left a white powder, which we recrystallized in a methanol-ethyl acetate mixture and then purified by TLC. Infrared analysis of the purified product gave a spectrum similar to that obtained by Leone et a!. (8) for aMT6s isolated from urine.
Synthesis of the immunogen.
The synthesized aMT6s was bound to BSA via Mannich's reaction (9 
Analytical Performance
We evaluated the specificity of the RIA by determining the relative potency of the compounds listed in Table  1 . To calculate the relative potency, we divided the quantity of cross-reactants displacing 50% of the antibody-bound 1251-labeled aMT6s by the quantity of aMT6s producing 50% displacement.
We assessed parallelism by comparing the displacement of a nocturnal plasma sample, diluted with charcoal-stripped plasma, with the values on the standard curve. We also assessed whether the plasma dilution curve could be superimposed on the standard curve. The specific activity of the iodinated aMT6s was assessed by the method of Joseph et al. (12) .
To ascertain analytical recovery, we added known amounts of aMT6s to a stock plasma pool, to give final concentrations of 457, 530, and 814 pmol/L, and then assayed.
Eight replicated plasma standard curves, one assay per day, were run to ascertainthe precisionofthe assay.
The least detectable concentration was defined as the concentration giving a displacement of 2 SD of counts from maximum binding.
Physiological Studies
In all cases, blood was collected into heparinized tubes, and plasma was separated by centrifugation and stored at -20 #{176}C until RIA.
We studiedthe dailyrhythm ofaMT6s in four young (ages 22-28 y) healthy volunteers. These study protocols had previously been approved by the National Ethics Committee.
Results
Assay Validation
The overall iodination yield was 35%. The concentratedtracer (15 mCiIL in methanol at -20 #{176}C) is stable for at least four months. We determined its specific activity to be 720 kCi/mol. All the rabbits immunized produced antisera after the second immunization.
After the fourth immunization, Plasma collected during the night and diluted with charcoal-stripped plasma gave the same displacement as that of the aMT6s standard curve when we assayed 100-4, samples of plasma directly (Figure 1 ).
Analytical recoveries of three different aMT6s concen-
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I -----.#{149} trations (457, 530, and 814 pmol/L) were 100 ± 7%, 103 ± 9%, and 109 ± 10%, respectively (mean ± SD, n = 6). Only 381 pmol of aMT6s per liter was necessary for a 50% displacement of the iodinated tracer. The least detectable concentration of aMT6s was 15 pmol!L (Figure 1) .
For an aMT6s concentration in plasma of 300 pmol/L, the intra-assay CV was 8% and the interassay CV was 12%.
Physiological Studies
In healthy men, aMT6s in plasma showed a circadian variation (Figure 2 
Discussion
In this paper, we describe a sensitive (detection limit to baseline values. The presence of aMT6s in plasma and the delay observed in the onset of the aMT6s profile compared with the melatonin profile are a consequence of the liver metabolism. Because a strong first-pass hepatic metabolism after oral administration of melatonrn (15) leads to a rapid decline of the concentrations in plasma, this direct RIA, used with the assay of melatonin,should be valuable in the development ofnew parenteral pharmaceutical formulations that minimize liver uptake and ensure a sustained release of the hormone.
